Immunotherapy protocols in lung cancer

Nandini Menon, Sharada Mailankody

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Immunotherapy has emerged as a valuable treatment option in many advanced malignancies (especially lung cancer). The PD-1 inhibitors (nivolumab and pembrolizumab) and the PD-L1 inhibitors (durvalumab and atezolizumab) have been approved for use in various cancers, alone or in combination with chemotherapy. The protocols for the PD-1/PD-L 1 blockers are listed below. The various indications for these PD-1/PD-L1 blockers, baseline evaluation, monitoring during therapy, and guidelines for the management of immune-related adverse events are described below.

Original languageEnglish
Pages (from-to)139-162
Number of pages24
JournalCancer Research, Statistics, and Treatment
Issue number2
Publication statusPublished - 01-07-2018

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Ophthalmology
  • Drug guides
  • Oncology(nursing)


Dive into the research topics of 'Immunotherapy protocols in lung cancer'. Together they form a unique fingerprint.

Cite this